Patient characteristics at non-Hodgkin lymphoma presentation
| Characteristic . | Value . |
|---|---|
| Patients, no. | 113 |
| Sex | |
| Male | 62 (55) |
| Female | 51 (45) |
| Patient age, y (range) | |
| Median | 61 (16-85) |
| 60 years or older | 60 (53) |
| Histologic subtype | |
| Diffuse large B-cell | 94 (83) |
| Follicular | 5 (4) |
| Burkitt | 3 (3) |
| Small lymphocytic | 2 (2) |
| Other* | 5 (4) |
| Not reported | 4 (4) |
| Disease stage | |
| I | 25 (22) |
| II | 16 (14) |
| III | 14 (12) |
| IV | 42 (37) |
| Not reported | 16 (14) |
| A and B symptoms | |
| A | 56 (50) |
| B | 36 (32) |
| Not reported | 21 (18) |
| ECOG performance status | |
| 0 | 15 (13) |
| 1 | 40 (35) |
| 2 | 15 (13) |
| 3 | 7 (6) |
| 4 | 0 (0) |
| Not reported | 36 (32) |
| IPI | |
| 0 | 4 (4) |
| 1 | 14 (12) |
| 2 | 11 (10) |
| 3 | 24 (21) |
| 4 | 8 (7) |
| 5 | 2 (2) |
| Not reported | 50 (44) |
| Serum LDH | |
| Normal | 23 (20) |
| Elevated | 33 (29) |
| Not reported | 57 (50) |
| E lesions | |
| No | 21 (19) |
| Yes | 75 (66) |
| Not reported | 17 (15) |
| Extranodal sites | |
| None | 12 (11) |
| 1 | 57 (50) |
| 2 or more | 29 (26) |
| Not reported | 15 (13) |
| Sites of extranodal involvement† | |
| GI tract | 18 (16) |
| Testes | 16 (14) |
| Bones | 15 (13) |
| Lungs/pleura | 14 (12) |
| Liver | 13 (12) |
| Kidneys/genitourinary/adrenal | 13 (12) |
| Skin/subcutaneous tissue | 12 (11) |
| Breast | 10 (9) |
| Bone marrow | 8 (7) |
| Ovaries | 3 (3) |
| Sinuses/orbit | 2 (2) |
| Not reported | 6 (5) |
| Characteristic . | Value . |
|---|---|
| Patients, no. | 113 |
| Sex | |
| Male | 62 (55) |
| Female | 51 (45) |
| Patient age, y (range) | |
| Median | 61 (16-85) |
| 60 years or older | 60 (53) |
| Histologic subtype | |
| Diffuse large B-cell | 94 (83) |
| Follicular | 5 (4) |
| Burkitt | 3 (3) |
| Small lymphocytic | 2 (2) |
| Other* | 5 (4) |
| Not reported | 4 (4) |
| Disease stage | |
| I | 25 (22) |
| II | 16 (14) |
| III | 14 (12) |
| IV | 42 (37) |
| Not reported | 16 (14) |
| A and B symptoms | |
| A | 56 (50) |
| B | 36 (32) |
| Not reported | 21 (18) |
| ECOG performance status | |
| 0 | 15 (13) |
| 1 | 40 (35) |
| 2 | 15 (13) |
| 3 | 7 (6) |
| 4 | 0 (0) |
| Not reported | 36 (32) |
| IPI | |
| 0 | 4 (4) |
| 1 | 14 (12) |
| 2 | 11 (10) |
| 3 | 24 (21) |
| 4 | 8 (7) |
| 5 | 2 (2) |
| Not reported | 50 (44) |
| Serum LDH | |
| Normal | 23 (20) |
| Elevated | 33 (29) |
| Not reported | 57 (50) |
| E lesions | |
| No | 21 (19) |
| Yes | 75 (66) |
| Not reported | 17 (15) |
| Extranodal sites | |
| None | 12 (11) |
| 1 | 57 (50) |
| 2 or more | 29 (26) |
| Not reported | 15 (13) |
| Sites of extranodal involvement† | |
| GI tract | 18 (16) |
| Testes | 16 (14) |
| Bones | 15 (13) |
| Lungs/pleura | 14 (12) |
| Liver | 13 (12) |
| Kidneys/genitourinary/adrenal | 13 (12) |
| Skin/subcutaneous tissue | 12 (11) |
| Breast | 10 (9) |
| Bone marrow | 8 (7) |
| Ovaries | 3 (3) |
| Sinuses/orbit | 2 (2) |
| Not reported | 6 (5) |
Values indicate numbers (%) of patients unless otherwise noted.
Other histologic subtypes were mantle cell (n = 1), mucosa-associated lymphoid tissue (n = 1), anaplastic large cell/T-cell (n = 1), poorly differentiated lymphocytic (n = 1), and diffuse large cell/follicular cell (n = 1).
Some patients had multiple sites of extranodal involvement.